Extra, Extra Read All About It: Renaming Gleason 6 as a noncancer
By Howard Wolinsky
Gleason 6 looks like a cancer. But it doesn’t act like one. So why call it cancer?
A report came out Monday in the Journal of Clinical Oncology on a campaign to reclassify Gleason 6 as noncancer to ease the minds of anxious patients and to protect them from financial toxicity from the insurance industry.
My former urologist, Dr. Scott Eggener, of the University of Chicago, was the lead author. I was a patient co-author.
(Actually, I have been impatient for this change since a life insurance company reduced my coverage and kept my premiums level when I was diagnosed almost 12 years ago.)
I wrote about this on Monday in TheActiveSurveillor.com: https://bit.ly/3MfNyrv
Associated Press weighed in: https://bit.ly/3jPcKJa
As did Medscape Medical News: https://wb.md/3OmJ9Vt
I wrote about this issue a year ago in MedPageToday: https://www.medpagetoday.com/special-reports/apatientsjourney/90601
I’d like you to share your opinion in the comments and answer the survey: “Should the cancer label be removed from Gleason 6?: https://www.surveymonkey.com/r/ZQHDQYK.
Finally, the webinar on the future of AS scheduled for 11 a.m. Eastern/5 p.m. CET on Friday, April 22 is filling up.
We have well over 300 registrants from 15 countries, including Brazil, Singapore, Hong Kong, India, Switzerland, Belgium, Italy. And of course USA and Canada.
"Your Voice in the Future of Active Surveillance," at 11 a.m.Eastern/4 p.m. GMT on this topic. April 22.
Register here: https://bit.ly/3ueT9bc
ASPI and AnCan are leading the way.
MaleCare has joined our endorsement team. ZERO/Us TOO has has given us a plug.
Should be a great meeting with Drs. Laurence Klotz, Peter Carroll, Peter Albertsen, Chris Bangma, Ola Bratt and many, many more.
Join us for an historic meeting.